The ATLAS study – A clinical trial for people who want to contribute to SOD1-ALS research

Biogen is conducting a clinical trial to evaluate the efficacy and safety…

Words Nienke Kramer.Published February 24, 2023
The ATLAS study – A clinical trial for people who want to contribute to SOD1-ALS research

Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) that definitely indicate the onset of ALS, but do carry a certain superoxide dismutase 1 (SOD1) gene variant.

Study duration

The maximum study duration is approximately six years and six months, including:

  • Up to 6 weeks screening
  • Up to 4 years and 3 months health monitoring
  • Up to 2 years study treatment period

The study is comprised of 4 parts as described below.

NF= Neurofiliment which is a group of proteins.

Investigational drug
  • Tofersen (BIIB067), an antisense oligonucleotide (ASO)
  • Designed to reduce the amount of SOD1 protein in the body
  • Given intrathecally, through a lumbar puncture
Key Eligibility Criteria

To be able to enroll in the ATLAS study (Part A), participants need to:

  • Not have any signs or symptoms of ALS (that definitely indicate onset of ALS)
  • Have a certain SOD1 mutation (that is associated with high/complete penetrance and rapid disease progression)
  • Be 18 years of age or older
  • Have a plasma NF level below the pre-defined threshold
All eligible participants will receive at no cost
  • Comprehensive study-related health evaluations and assessments, including genetic testing
  • Investigational drug or placebo
  • All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available.

Read more on the ATLAS trial here or reach out to atlas@tricals.org for more information.


Share

Related news

ENCALS consensus statement on NurOwn
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS, […]
Story behind the participant: Peter Ambühl
Story behind the participant: Peter Ambühl
Many clinical trials are looking for participants. In this new interview series, […]
Apellis reports discontinuation of MERIDIAN study
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of […]
Recording of virtual meeting - Adherence and retention in ALS clinical trials
Recording of virtual meeting - Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention […]